Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

4(66.7%)

Phase 1

1(16.7%)

N/A

1(16.7%)

6Total

Phase 4(4)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03333642Not ApplicableUnknown

Surgery Treatment of Type 2 Diabetes Mellitus Patients With Grade 1 Obesity and Overweight

Role: lead

NCT04511429Unknown

COVID-19 in Immunosuppressed Children

Role: collaborator

NCT03586817Phase 4Unknown

PALONOSETRON X FOSAPREPITANT IN PONV

Role: lead

NCT02541019Phase 4Completed

Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for the Prophylaxis of Postoperative Nausea and Vomiting (PONV) in Women Over 60 Years Undergoing Laparoscopic Cholecystectomy

Role: lead

NCT02989272Phase 4Unknown

Effect of Pre-treatment With Magnesium Sulfate on the Duration of Deep Neuromuscular Blockade With Rocuronium

Role: lead

NCT02034786Phase 1Unknown

Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid

Role: collaborator

NCT01828385Phase 4Completed

Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex

Role: collaborator

All 7 trials loaded